KYTX
USDKyverna Therapeutics Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$6.670
Máximo
$6.930
Mínimo
$6.670
Volumen
0.31M
Fundamentos de la Empresa
Capitalización de Mercado
291.5M
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
0.57M
Bolsa
NMS
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $31
Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics with a Overweight and raises the price target from $27 to $31.
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically meaningful
HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $20
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics with a Buy and raises the price target from $10 to $20.
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate a
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
EMERYVILLE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases,
Acciones Relacionadas
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.